Novo Nordisk stock news
On May 28, 2026, France announced a landmark decision to provide state reimbursement for weight--loss medications, including Novo Nordisk's Wegovy, making it the first European Union nation to offer such coverage. The policy applies to patients with a BMI of 40 or higher, or a BMI of 35 with associated comorbidities. This initiative is projected to cost approximately €100 million annually and could provide access to nearly one million eligible beneficiaries, significantly expanding Novo Nordisk's commercial footprint and long--term growth prospects in the European obesity market.